Your CREON Connection

This virtual experience provides access to educational presentations, plus opportunities to connect live with colleagues and Exocrine Pancreatic Insufficiency (EPI) experts.

Scroll to experience

Calendar icon

10+ Years of Experience

as the first pancreatic enzyme replacement
therapy (PERT) to receive FDA approval2

Script Counter

Patients Prescribed

since FDA approval in 20093

9 of 10 GI's Prescribe CREON

Nearly 9 out of 10

GIs prescribe CREON more than other PERTs4

Per Oct '18-Sept '19 analysis of 10,053 GIs, 86% of
surveyed GIs had greater than 50% of their PERT
prescriptions filled as CREON.

Circle Chart Showing to 97%

Access +and
coverage for 97%

of patients with the lowest
branded co-pay4*

Chart Showing 95%

96% of insured patients

have unrestricted access
(with no prior authorization)4†‡

Number 1 Ribbon

#1 Prescribed pert5

*“Lowest branded co-pay” means the product is in the formulary tier status designated by the insurer as the lowest branded co-pay in the therapeutic class.

Rates reflect patients insured through Commercial, Medicare Part D, and Medicaid.

Unrestricted access varies by channel: Commercial (98%), Medicare Part D (98%), Fee-for-service Medicaid (92%), Managed Medicaid (85%).

Attend a
Virtual Roundtable

Have questions about EPI or CREON? Now you can connect live for a virtual conversation led by an expert key opinion leader (KOL). Space is limited so reserve your spot today!

Select a KOL to view available dates and times

Alejandro Suarez

Alejandro Suarez

Gastroenterology and Internal Medicine

Charleston, SC

Mohamed Othman, MD

Mohamed Othman, MD


Houston, TX

Tyler Stevens, MD

Tyler Stevens, MD

Gastroenterology, Hepatology & Nutrition

Cleveland, OH

Kalpesh Patel, MD

Kalpesh Patel, MD

Gastroenterology and Hepatology

Houston, TX

Doctor speaking at podium

Register for Upcoming
Educational Presentations

Please join us for an AbbVie educational presentation about CREON and EPI. Register today to reserve your space.

View Events

Additional CREON (pancrelipase) Information1

Pills icon


For many adult patients, 36K can be the appropriate strength.

2 capsules with every meal
1 capsule with every snack*

Take during every meal and snack.

Dosing Details
Book and Magnifying glass icon


CREON efficacy has been studied extensively across various patient populations.

PERTs are not interchangeable.

Efficacy Data
Alert icon


CREON safety has been studied extensively across various patient populations.

Safety Data
Phone Conversation icon

Patient Support

CREON On Course makes it easy and convenient for patients with EPI to get financial, multivitamin, and educational support.

CREON Support

*Patients weighing <160 lb may require a lower lipase unit starting dose. Patients weighing >315 lb may require a higher lipase unit starting dose.

Forever Thankful. Thank you healthcare workers for your hard work and dedication to helping patients - AbbVie

Indications and Important Safety Information


CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Important Safety Information

  • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
  • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
  • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
  • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
  • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
  • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
  • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
  • CREON is not interchangeable with any other pancrelipase product.

Please see Full Prescribing Information including Medication Guide.

References: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc. 2. Center for Drug Evaluation and Research. Approval letter, NDA 20-725. U.S. Food and Drug Administration website. Published April 30, 2009. Accessed February 14, 2020. 3. Data on file. ZS Associates Analysis. October 2019. 4. Data on file. Managed Markets Insight & Technology, LLC. February 2020. 5. Data on file. IMS Health. IMS National Prescription Audit. September 2019.

Indications and Important Safety Information